Safety, Efficacy, and Pharmacodynamics of a 60-Minute Infusion of Carfilzomib for Progressive Multiple Myeloma
Status:
Unknown status
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1/2, multicenter, open label, dose-escalation, nonrandomized study to
evaluate the safety, pharmacodynamics, and efficacy of a 60-minute infusion of carfilzomib
for patients with progressive multiple myeloma.